AC-203 clinical trial enrollment starts for EBS patients
A Phase 2/3 clinical trial testing AC-203 (diacerein 1% ointment) in people with epidermolysis bullosa simplex (EBS) is recruiting participants. The trial, EBShield (NCT06073132), seeks to enroll approximately 80 people ages 6 months and older with localized, severe, or intermediate EBS. To be eligible for participation, patients must…